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We determined the macrolide resistance phenotypes of 241 clinical isolates of erythromycin-resistant en-
terococci (MICs, >1 g/ml), including 147 Enterococcus faecalis strains and 94 Enterococcus faecium strains,
collected from a hospital in Seoul, Korea, between 1999 and 2000. By the erythromycin (40 g)-josamycin (100
g) double-disk test, 93 strains were assigned to the constitutive macrolide, lincosamide, and streptogramin
B (MLSB) resistance (cMLSB) phenotype, and the remaining 148 strains were assigned to the inducible MLSB
resistance (iMLSB) phenotype. Of the strains with the iMLSB phenotype, 36 exhibited a reversibly inducible
MLSB (riMLSB) phenotype, i.e., blunting of the erythromycin zone of inhibition, which indicates that the
16-membered-ring macrolide josamycin is a more effective inducer than the 14-membered-ring macrolide
erythromycin. Sequence analysis of the regulatory regions of the erm(B) genes from all of the strains exhibiting
the riMLSB phenotype revealed not only erm(Bv) [where v represents variant; previously erm(AMR)] (n  13),
as reported previously, but also three kinds of erm(B) variants, which were designated erm(Bv1) (n  17),
erm(Bv2) (n  3), and erm(Bv3) (n  3), respectively. In lacZ reporter gene assays of these variants, the
16-membered-ring macrolide tylosin had stronger inducibility than erythromycin at >0.1 g/ml. These find-
ings highlight the versatility of erm(B) in induction specificity.
Cross-resistance to macrolide, lincosamide, and strepto-
gramin B (MLSB) antibiotics is mediated by 23S rRNA muta-
tions or the erm genes, which encode 23S rRNA methylases.
The expression of MLSB resistance by the erm genes can be
either constitutive or inducible, depending on the regulatory
region located upstream of the structural gene. In inducible
resistance, the specificity of induction differs according to the
nature of the regulatory region. The erm(A) and erm(C) genes,
the predominant determinants of MLSB resistance in staphy-
lococci, are most often induced in the presence of 14-mem-
bered-ring macrolides and the lincosamide celesticetin, but not
the 16-membered-ring macrolides and the lincosamide linco-
mycin (1, 8, 23, 24). Mutants of Staphylococcus aureus selected
in the laboratory were reported to be induced by lincomycin
and the 16-membered-ring macrolide carbomycin (22); and a
recently found clinical strain of S. aureus with erm(A) had
inducible cross-resistance to the 14-membered-ring macrolide
erythromycin, the lincosamides clindamycin and lincomycin,
and the streptogramin B quinupristin (5). The erm(D) gene is
induced by the 14-membered-ring macrolides erythromycin
and oleandomycin but is not induced by either the 16-mem-
bered-ring macrolide tylosin or the lincosamides clindamycin
and lincomycin (6). Transcription of the erm(S) gene in the
tylosin producer Streptomyces fradiae is autoinducible by tylo-
sin (10). The erm(V) gene from Streptomyces viridochromo-
genes is induced by the 14- and 16-membered-ring macrolides
and celesticetin (8). Interestingly, all MLSB antibiotics induce
erm(B) (11), the most widely distributed erm determinant in
Streptococcus pneumoniae (11), Streptococcus pyogenes (9), and
Enterococcus (18). We previously reported that erm(Bv) [where v
represents variant; previously erm(AMR)], the variant of
erm(B) from a clinical isolate of Enterococcus faecalis, was
induced more strongly by the 16-membered-ring macrolides
josamycin, tylosin, and kitasamycin than by erythromycin (16,
17). This alteration of the induction specificity was due to a
mutation encoding an arginine-to-cysteine change in the sev-
enth codon of the putative leader peptide preceding the meth-
ylase gene.
In this work, we looked at the unexpected rate of the MLSB
resistance phenotype in which the 16-membered-ring macro-
lides are more effective inducers than the 14-membered-ring
macrolides in enterococcal clinical isolates. We also investi-
gated the molecular basis of the alteration of induction spec-
ificity in these strains by DNA sequence analyses of the regu-
latory regions of erm(B) and lacZ reporter gene assays.
MATERIALS AND METHODS
Bacterial strains. A total of 241 clinical isolates of erythromycin-resistant
enterococci, including 147 Enterococcus faecalis isolates and 94 Enterococcus
faecium isolates, were collected from the Severance Hospital in Seoul, Korea,
between May 1999 and January 2000. Multiple isolates from the same patient
were avoided. Erythromycin resistance (MIC, 1 g/ml) was identified by the
agar dilution method (see below).
Antimicrobials and MIC testing. The following antimicrobial agents were used
in this study: clarithromycin (Abbott Laboratories, Abbott Park, Ill.), erythro-
mycin and tylosin (Sigma, St. Louis, Mo.), josamycin and kitasamycin (ICN
Biomedicals, Aurora, Ohio), and rokitamycin (Asahi Kasei Co., Ltd., Tokyo,
Japan). The MICs were determined by the agar dilution method in Mueller-
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Hinton agar (Difco, Detroit, Mich.) by the procedure recommended by the
National Committee for Clinical Laboratory Standards (15).
Determination of resistance phenotype. Erythromycin (40 g) and josamycin
(100 g) disks were placed 5 to 10 mm apart on brain heart infusion (BHI) agar
(Difco), and the plates were incubated aerobically at 37°C for 18 h. The absence
of a significant zone of inhibition around the two disks was taken to indicate the
constitutive type of MLSB resistance (cMLSB phenotype). Blunting of the josa-
mycin zone of inhibition proximal to the erythromycin disk or blunting of the
erythromycin zone of inhibition proximal to the josamycin disk was taken to
indicate the inducible type of MLSB resistance (iMLSB phenotype). The iMLSB
phenotype with blunting of the erythromycin zone of inhibition proximal to the
josamycin disk was taken to indicate the reversibly inducible type of MLSB
resistance (riMLSB phenotype).
Growth curves. Bacterial cultures grown overnight in BHI broth without an-
tibiotic were diluted to an optical density at 590 nm (OD590) of approximately 0.2
in BHI broth with 0.1 g of tylosin or erythromycin per ml. After induction by
incubation for various times at 37°C, the cultures were diluted to an OD590 of
approximately 0.05 in BHI broth with 500 g of erythromycin per ml. Growth at
37°C was monitored by measuring the turbidity of the culture at OD590 for up to
6 h.
Sequence analysis of the erm(B) gene regulatory regions and construction of
erm(B)-lacZ reporter plasmids. The regulatory regions of the erm(B) genes from
36 strains with an riMLSB phenotype were amplified with Vent DNA polymerase
(New England Biolabs) and primers SR3 (5-CTTAGAAGCAAACTTAAGAG
TGTGT-3) (19) and SR71 (5-AATTTCGTAAACGGTATCGGTTTCT-3).
The 430-bp PCR products were purified with a QIAquick PCR purification kit
(Qiagen) and were sequenced by using primer SR71 in a DNA sequencer (ABI
PRISM 310; Applied Biosystems). After a comparison of the sequences, we
selected three kinds of PCR products with novel sequences from E. faecalis
C6608, Enterococcus faecium 3327, and E. faecalis U326, respectively. To con-
struct in-phase fusions of erm(B) with lacZ, the PCR products from each selected
strain were ligated to the SmaI site of pMM156 containing a promoterless lacZ
gene (4). The resultant ligation products were introduced by electroporation into
Escherichia coli CSH26, and transformants were selected on Luria-Bertani (LB)
agar plates containing chloramphenicol (10 g/ml). The transformants on each
plate were pooled, and the plasmid DNAs were isolated. These pooled plasmid
DNAs were introduced into Bacillus subtilis BR151 as described previously (2),
and the transformants were selected on LB agar containing an inducing concen-
tration of josamycin (0.1 g/ml), 5-bromo-4-chloro-3-indolyl--D-galactopyrano-
side (40 g/ml), and chloramphenicol (10 g/ml). A single blue colony of each
strain was selected for the -galactosidase induction assay. The sequences of all
recombinant plasmids were confirmed by DNA sequencing.
-Galactosidase induction assays. Measurements of induction were per-
formed for pEZ1, pEZ3, and pEZ4, which were constructed previously (16), as
well as for the three plasmids constructed as described above. Plasmids pEZ1
and pEZ3 contain the upstream portion, including the regulatory regions, of
erm(Bv) and erm(B) from Tn917, respectively, fused in frame with the lacZ gene
in pMM156. Plasmid pEZ4 is identical to pEZ3 except for the lack of duplication
of the TAAA sequence in the leader peptide. Cultures of B. subtilis BR151
harboring each erm(B)-lacZ fusion plasmid were grown to early log phase at 37°C
in SPII medium (2). Cultures were induced for 120 min with either erythromycin
or tylosin at concentrations from 1 ng/ml to 10 g/ml, as indicated in Fig. 4.
-Galactosidase assays were carried out as described previously (14). Specific
activities were expressed in Miller units and were averaged from at least three
independent assays.
RESULTS AND DISCUSSION
Identification of macrolide resistance phenotypes. Since
E. faecalis is intrinsically resistant to clindamycin (21), an
erythromycin (40 g) and josamycin (100 g) double-disk test
instead of a triple-disk test with erythromycin, josamycin, and
clindamycin disks was performed to determine the resistance
phenotypes of the enterococci. Of the 241 strains of erythro-
mycin-resistant enterococci tested, 93 (39%) were assigned to
the cMLSB phenotype and 148 (61%) were assigned to the
iMLSB phenotype; among the latter strains, 36 (15%) showed
the riMLSB phenotype. The rate of occurrence of the iMLSB
phenotype might increase by the growth curve test. Isolates
with the riMLSB phenotype exhibited blunting of the erythro-
mycin zone of inhibition proximal to the josamycin disk (Fig.
1). The unexpected rate of enterococcal isolates with the
riMLSB phenotype indicates that this novel macrolide resis-
tance pattern is indeed disseminated among the enterococci in
a Korean hospital.
When disks with lower amounts of drug (erythromycin, 15
g; josamycin, 20 g) were used, only 5 isolates presented the
riMLSB phenotype, whereas the other 31 isolates exhibited a
false cMLSB phenotype. Considering that these 31 isolates
exhibited the riMLSB phenotype when they were tested with
disks containing large amounts of drugs, the amounts of drug
in the disks might be a critical factor in finding isolates with an
riMLSB phenotype. Also, these results indicate that most of
the 36 isolates with the riMLSB phenotype are highly resistant
to both drugs.
The resistance inducibilities of erythromycin and tylosin
were tested with 3 strains selected from among the 36 strains
with the riMLSB phenotype by measuring their growth rates in
broth. After exposure to a subinhibitory concentration (0.1
g/ml) of either erythromycin or tylosin for various times, the
cells were challenged with a high concentration (500 g/ml) of
erythromycin. E. faecalis R703 acquired resistance to the mac-
rolide more rapidly when resistance was induced with tylosin
than when it was induced with erythromycin; i.e., tylosin was a
more potent inducer than erythromycin (Fig. 2). Similar results
were obtained with the remaining strains, E. faecalis U326 and
E. faecalis C6593 (data not shown). However, when the chal-
lenge concentration was decreased to 100 g/ml, these kinetics
of induction were not observed because the growth of the
bacteria in which resistance was not induced was scarcely in-
hibited.
Resistance to macrolide antibiotics. In a previous report
(17), the MICs of the 16-membered-ring macrolides josamycin,
tylosin, kitasamycin, and rokitamycin for E. faecalis 373, the
first clinical isolate identified to contain erm(Bv), were at least
1,024 g/ml, while the MICs of the 14-membered-ring macro-
lides erythromycin and clarithromycin were 16 g/ml. In con-
trast, all 36 strains with the riMLSB phenotype tested in this
study were highly resistant (MICs, 512 g/ml) to erythromy-
cin and clarithromycin as well as to josamycin, tylosin, kitasa-
mycin, and rokitamycin. Thus, the high level of resistance of
the isolates with the riMLSB phenotype might explain why this
phenotype was most easily identified when disks with high
FIG. 1. riMLSB phenotype of erythromycin-resistant enterococcal
isolates. The disks contained 40 g of erythromycin (E) and 100 g of
josamycin (J).
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doses in double-disk tests or high challenge concentrations in
growth kinetic assays were used.
Sequence analysis of regulatory regions of erm(B) genes.
The 36 isolates with the riMLSB phenotype were analyzed for
the presence of erm(B) by PCR with erm(B)-specific primers
SR3 and SR71. For all isolates, an amplicon with the expected
molecular size of 430 bp was obtained. The PCR product
contains the putative promoter, the sequence encoding the
leader peptide, and the first 108 nucleotides of the methylase
gene. The nucleotide sequences of the PCR products were
determined and are compared with that of erm(B) from Tn917
(GenBank accession no. M11180) in Fig. 3. Four groups of
variations were detected. In the first variation, the sequences of
the fragments amplified from 13 isolates were identical to that
of erm(Bv), which had a C-to-T transition that resulted in an
amino acid change from Arg to Cys at the seventh codon of the
putative leader peptide. The second variation, observed for 17
isolates and designated erm(Bv1), had a duplication of CAAA
TGCGTTAT in the leader peptide, resulting in the duplication
of four amino acids (Gln, Met, Arg, Tyr). This 12-nucleotide
duplication was also observed in an erm(B) variant [previously
erm(BC) from E. coli] (3). In addition, erm(Bv1) had two base
substitutions in the sequence encoding the leader peptide,
which led to changes in the corresponding amino acids. The
third variation, observed for three isolates and designated
erm(Bv2), was similar to erm(Bv1). In erm(Bv2), the 25th nu-
cleotide of the sequence encoding the erm(Bv1) leader pep-
tide, cytosine, was changed to adenine, and only one of the two
point mutations found in erm(Bv1) was observed. The fourth
variation, detected in the three remaining isolates and desig-
nated erm(Bv3), had a C-to-T transition that led to a single
amino acid change from Thr to Ile at the 14th codon of the
leader peptide and a point mutation located downstream from
the leader peptide.
Meanwhile, we sequenced the structural erm(B) genes from
seven riMLSB strains: two with erm(Bv), three with erm(Bv1),
one with erm(Bv2), and one with erm(Bv3). In all erm(Bv) and
erm(Bv3) sequences that were sequenced, the coding se-
quences of the methylase genes were identical to that of Tn917.
All erm(Bv1) sequences had a substitution of Thr (ACT) for Ile
(ATT) at codon 75 and three silent mutations at codons 6, 74,
and 667 (AAA to AAG, AAC to AAT, and ACT to ACC,
respectively). In erm(Bv2), two mutations at codons 74 and 75
found in erm(Bv1) were observed. Although it was not exam-
ined whether the amino acid substitution at codon 75 of the
methylase gene has a role in the expression of various resis-
tance phenotypes, it is likely that the changes in the regulatory
region, including the leader peptide, are major causes of the
alteration of induction specificity, on the basis of the following
data from erm(B)-lacZ fusion experiments.
A translational attenuation model was proposed for the reg-
ulation mechanism of erm(B) (11). The expression of erm(C) is
controlled by translational attenuation, in which alterations in
the critical sequence of the leader peptide can affect the in-
duction efficiency of inducer antibiotics (12, 13). This notion
might be applied to the expression of erm(B). The replacement
of Val with Ile at position 19 of the erm(Bv1) and erm(Bv2)
leader peptides was also observed in pAM77 (7), and thus, it is
not thought to have much of an effect on the specificity of
induction. Therefore, the 4-amino-acid duplication in the
leader peptides of erm(Bv1) and erm(Bv2) is likely to be re-
sponsible for the switch in induction specificity. The codon
change at residue 14 of the leader peptide of erm(Bv3) is
probably associated with the efficiency of induction by macro-
lides because it is the sole mutation in the leader peptide.
Taken together, the sequence analysis results suggest that the
critical region of erm(B) for induction contains at least the
codons for residues 7 to 14 of the leader peptide.
-Galactosidase induction assays. To compare the induc-
tion of erm(B) from Tn917 by the 14- and 16-membered-ring
macrolides with those of the four variants, we performed -ga-
lactosidase assays with reporter constructs in which the meth-
ylase genes were translationally fused with E. coli lacZ. The
-galactosidase activities were measured after 120 min of in-
duction with various concentrations of either erythromycin or
tylosin (Fig. 4). For plasmid pEZ3 (16), which has the erm(B)
sequence from Tn917, although erythromycin was a stronger
inducer than tylosin at 1 and 10 ng/ml, the inducibilities of
erythromycin and tylosin were similar at 0.1 g/ml. At the
optimum concentrations (0.1 and 0.2 g/ml), both drugs were
effective inducers for pEZ3, while erythromycin was a stronger
inducer than tylosin for pEZ4 (16), which differs from pEZ3 by
the lack of duplication of the TAAA motif in the leader pep-
tide. In contrast to erm(B) from pAM77, that from Tn917 has
a duplication of TAAA within the leader peptide-coding se-
quence, resulting in a peptide 9 amino acids shorter. Consis-
tent with a previous report (16), the level of induction obtained
with the erm(B)-lacZ fusion, which has the TAAA duplication
(pEZ3), was higher than that obtained with the erm(B)-lacZ
fusion, which has the single TAAA motif (pEZ4). Thus, the
FIG. 2. Growth curves for E. faecalis R703 with erm(Bv). The strain
was induced with 0.1 g of tylosin per ml (A) and 0.1 g of erythro-
mycin per ml (B) for 0 (solid circles), 15 (solid squares), 60 (solid tri-
angles), and 120 (solid diamonds) min. The cultures were then chal-
lenged with 500 g of erythromycin per ml for 6 h.
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TAAA duplication appears to affect the induction specificity as
well as the level of expression of erm(B). For pEZ1 (16), the
erm(Bv)-lacZ fusion construct, the rates of -galactosidase ex-
pression were similar at low concentrations of both drugs (1
and 10 ng/ml). At 0.1 g/ml, however, tylosin had a higher
induction efficiency than erythromycin. Similar induction pat-
terns were also shown for pEZR-1, pEZR-2, and pEZR-3,
which carry the erm(Bv1)-lacZ, erm(Bv2)-lacZ, and
erm(Bv3)-lacZ fusions, respectively. In general, when the
concentration of the inducer was low (1 and 10 ng/ml), eryth-
romycin was a more potent inducer of these erm(B) variants
than tylosin or had an induction efficiency equivalent to that of
tylosin. In contrast, at inducer concentrations 0.1 g/ml or
higher, the expression of the erm(B) variants was more strongly
induced by tylosin than by erythromycin. These data show the
correlation between the inducer concentration and the induc-
tion specificity in erm(B) and the versatility of erm(B) in in-
duction. We also assessed induction as a function of time (0 to
120 min), but there was no significant time-dependent effect on
the inducibility of erythromycin and tylosin for any of the
constructs (data not shown).
There were drastic differences in the induced levels of ex-
pression among the erm(B) variants (Fig. 4). The basal level of
erm(B) expression could be influenced by mutations in the
putative promoter or the region forming a stem-loop structure,
which might sequester the ribosome binding site and the start
FIG. 3. Sequences of erm(Bv), erm(Bv1), erm(Bv2), and erm(Bv3) in comparison with the sequences of Tn917 and pAM77. Only differences
from the sequence of Tn917 are indicated. Gaps are indicated by dashes.
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codon for the methylase. However, such mutations were not
found in the erm(B) sequences of the 36 strains analyzed in this
study in comparison with the erm(B) sequence in Tn917 (Fig.
3). Thus, it is likely that a mutation in the leader peptide-
coding sequence affects the secondary structure of putative
upstream attenuators and, consequently, the downstream
structure, which sequesters the initiation sequence for transla-
tion of the methylase gene. Also, this mutation could alter the
efficiency or location of ribosome stalling, and therefore, the
secondary structure of the putative attenuator would change.
All of the 36 isolates with the riMLSB phenotype exhibited
inducible resistance to macrolide antibiotics and were highly
resistant to these drugs (MICs, 512 g/ml). It is possible that
the high level of resistance results from a high basal level of
expression. However, the level of expression of erm(Bv3) was
quite low compared with those of the other erm(B) variants
FIG. 4. -Galactosidase (-gal) activity for B. subtilis BR151 carrying plasmids with erm(B)-lacZ fusions after 120 min of induction with various
concentrations of erythromycin (solid circles) and tylosin (open circles).
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(see the result for pEZR-3 in Fig. 4). Also, as mentioned
above, none of the erm(B) variants had a mutation in the pu-
tative promoter or the attenuator at the 3 end. Moreover, the
13 isolates harboring erm(Bv) found in this study had a very
high level of resistance to the 14-membered-ring macrolide, in
contrast to the levels of resistance of a strain that carries the
same erm(Bv) found previously, E. faecalis 373 (17). This dis-
crepancy may be accounted for by differences in the genetic
backgrounds of the hosts or the copy number of the erm(B)
gene. It is conceivable that the expression of erm(B) can be
changed by mutations not only of the regulatory region encom-
passing the leader peptide but also of a possible regulator, for
example, open reading frame ORF3 followed by the methylase
gene in Tn917 (20).
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